Latest news with #Progyny
Yahoo
7 hours ago
- Business
- Yahoo
Progyny (PGNY) Stock Is Up, What You Need To Know
What Happened? Shares of fertility benefits company Progyny (NASDAQ:PGNY) jumped 3.1% in the afternoon session after continued positive momentum as the company reported stronger-than-expected second-quarter results and raised its full-year 2025 revenue and earnings guidance. The fertility benefits leader reported stronger-than-expected second-quarter results and raised its outlook for 2025. Progyny posted adjusted Q2 earnings of $0.48 per share, beating analyst estimates, on revenue of $332.9 million. Following the strong performance, the company boosted its full-year guidance, now projecting revenue of around $1.25 billion at the midpoint, up from its previous forecast of $1.21 billion. Management also raised its full-year adjusted earnings guidance to approximately $1.74 per share at the midpoint. This updated forecast highlights robust underlying growth driven by expanding demand for its fertility and family building benefits. After the initial pop the shares cooled down to $24.15, up 3.1% from previous close. Is now the time to buy Progyny? Access our full analysis report here, it's free. What Is The Market Telling Us Progyny's shares are somewhat volatile and have had 12 moves greater than 5% over the last year. In that context, today's move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business. The previous big move we wrote about was 5 days ago when the stock gained 5.1% on the news that markets continued to rally amid growing speculation of an impending interest rate cut by the Federal Reserve. Following a favorable Consumer Price Index (CPI) report, investors are increasingly betting on a rate reduction next month, a sentiment amplified by U.S. Treasury Secretary Scott Bessent's call for a significant cut. This has fueled a 'risk-on' environment across Wall Street. Lower interest rates are typically beneficial for growth-oriented sectors like healthcare, as they reduce the cost of borrowing for research and innovation and increase the present value of future earnings. Progyny is up 36.2% since the beginning of the year, and at $24.15 per share, it is trading close to its 52-week high of $24.82 from September 2024. Investors who bought $1,000 worth of Progyny's shares 5 years ago would now be looking at an investment worth $824.65. Unless you've been living under a rock, it should be obvious by now that generative AI is going to have a huge impact on how large corporations do business. While Nvidia and AMD are trading close to all-time highs, we prefer a lesser-known (but still profitable) semiconductor stock benefiting from the rise of AI. Click here to access our free report on our favorite semiconductor growth story. Sign in to access your portfolio
Yahoo
06-08-2025
- Business
- Yahoo
Progyny Earnings: What To Look For From PGNY
Fertility benefits company Progyny (NASDAQ:PGNY) will be announcing earnings results this Thursday after market hours. Here's what to look for. Progyny beat analysts' revenue expectations by 5% last quarter, reporting revenues of $324 million, up 16.5% year on year. It was a satisfactory quarter for the company, with a solid beat of analysts' sales volume estimates but a slight miss of analysts' full-year EPS guidance estimates. Is Progyny a buy or sell going into earnings? Read our full analysis here, it's free. This quarter, analysts are expecting Progyny's revenue to grow 5.4% year on year to $320.4 million, slowing from the 8.8% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $0.43 per share. The majority of analysts covering the company have reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Progyny has missed Wall Street's revenue estimates four times over the last two years. Looking at Progyny's peers in the health insurance providers segment, some have already reported their Q2 results, giving us a hint as to what we can expect. CVS Health delivered year-on-year revenue growth of 8.4%, beating analysts' expectations by 5.1%, and Clover Health reported revenues up 34.1%, topping estimates by 1.7%. CVS Health's stock price was unchanged following the results. Read our full analysis of CVS Health's results here and Clover Health's results here. Debates around the economy's health and the impact of potential tariffs and corporate tax cuts have caused much uncertainty in 2025. While some of the health insurance providers stocks have shown solid performance in this choppy environment, the group has generally underperformed, with share prices down 3.1% on average over the last month. Progyny is up 8.9% during the same time and is heading into earnings with an average analyst price target of $26.75 (compared to the current share price of $23.35). When a company has more cash than it knows what to do with, buying back its own shares can make a lot of sense–as long as the price is right. Luckily, we've found one, a low-priced stock that is gushing free cash flow AND buying back shares. Click here to claim your Special Free Report on a fallen angel growth story that is already recovering from a setback. StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
30-07-2025
- Business
- Yahoo
New Progyny Study Reveals Gap Between Perceptions and Realities in Women's Health Benefits Coverage
Increased awareness of expanded women's health and family building solutions has led to a growing disconnect between most wanted employee benefits and employer offerings NEW YORK, July 30, 2025 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a global leader in women's health and family building solutions, today announced the results of their new national Women in the Workplace research conducted in partnership with Dynata, the world's largest first-party data company for insights, activation, and measurement. The study reveals a persistent gap between what employees want from their women's health benefits, and what employers believe they are providing. Specifically, results show that 81% of HR leaders say they're committed to advancing women's health and well-being in the workplace, but only 52% of working women believe their benefits make healthcare affordable. 'The trend of women seeking out and even changing jobs for better benefits has been a persistent one the past few years. This study proves that women know what they want, and they are raising their voices. Simultaneously, HR leaders are aware of this trend and are eager to expand their women's health benefits to get ahead in talent recruitment and retention,' said Katie Higgins, Chief Commercial Officer, Progyny. 'Where the mark in women's health benefits may be missed is with the absence of a unified benefit that provides success to both sides – covers the continuum of care for women, increases engagement, results in clinical impact, and provides cost-control.' According to the study, while most employers express a strong interest in supporting women's health, they are unknowingly falling short in delivering access to specialized care, clear benefits navigation, and the personalization employees expect, particularly across critical life stages like fertility, pregnancy, and menopause. It's not enough to simply offer a women's health benefit or access to a digital tool – the benefit needs to be designed and implemented with intention. This new research shows leading concerns among female employees include: A significant gap exists. While 83% of women say benefits that support coaching and treatment for menopause are important, only 12% say their employer does a good job in providing limits impact. Nearly one in four women (24%) who wanted to use a benefit gave up because it was too complex to understand or access. Integration matters. 83% of women and 88% of employers agree that centralized support from one place would make women's health benefits more effective. The stakes are high. 69% of benefit managers said women's health benefits are extremely important to their strategy of attracting and retaining younger employees. One employer respondent summed it up: 'I feel that the lack of dedicated resources, such as an internal women's health advocate or specialist, prevents us from delivering a truly comprehensive women's health program.' The data shows that employers need a solution that brings it all together: personalized care from top-tier specialists, built-in education, connected services, and ongoing support. 'We speak with employers who are deeply committed to supporting their workforce, but many don't know where to start and feel the goal post keeps moving, "said Higgins. 'This research highlights where employee needs are greatest and shows that offering support across the full women's health journey is now table stakes. Leading organizations aren't just keeping up with trends – they're investing strategically to improve outcomes, control costs, and retain talent.' To view the full study results and learn how Progyny can help your organization bridge the gap in family building and women's health benefits, visit About this research: 1,202 women ages 18-65; US residents; with private health insurance, employed full-time at US employers with 250 or more employees were surveyed in September 2024 with a +/- 2.9% margin of error at a 95% confidence level. 252 benefits-decision makers ages 25+ whose primary role is HR or Admin/Management, involved in health insurance or wellness benefits; work in US public/private/government businesses (excluding non-profits); company in business 1+ years) employed full-time at employers with 250 or more employees were surveyed in September 2024 with a +/- 6.3% margin of error at a 95% confidence level. About Progyny Progyny (Nasdaq: PGNY) is a global leader in women's health and family building solutions, trusted by the nation's leading employers, health plans and benefit purchasers. We envision a world where everyone can realize their dreams of family and ideal health. Our outcomes prove that comprehensive, inclusive, and intentionally designed solutions simultaneously benefit employers, patients, and physicians. Our benefits solution empowers patients with concierge support, coaching, education, and digital tools; provides access to a premier network of fertility and women's health specialists who use the latest science and technologies; drives optimal clinical outcomes; and reduces healthcare costs. Headquartered in New York City, Progyny has been recognized for its leadership and growth as a TIME100 Most Influential Company, CNBC Disruptor 50, Modern Healthcare's Best Places to Work in Healthcare, Forbes' Best Employers, Financial Times Fastest Growing Companies, Inc. 5000, Inc. Power Partners, and Crain's Fast 50 for NYC. For more information, visit About Dynata Dynata is the world's largest first-party data company for insights, activation and measurement. With a reach that encompasses nearly 70 million consumers and business professionals globally, and an extensive library of individual profile attributes collected through surveys, Dynata is the cornerstone for precise, trustworthy quality data. The company has built innovative data services and solutions around its robust first-party data offering to bring the voice of the customer to the entire marketing continuum — from uncovering insights to activating campaigns and measuring cross-channel marketing ROI. Dynata serves more than 6,000 market research, media and advertising agencies, publishers, consulting and investment firms and corporate customers in North America, South America, Europe and Asia-Pacific. Learn more at For Further Information, Please Contact: Media: Alexis Ford media@ Investors: James Hart investors@ A photo accompanying this announcement is available at in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
19-07-2025
- Business
- Yahoo
Why Progyny (PGNY) Stock Is Falling Today
What Happened? Shares of fertility benefits company Progyny (NASDAQ:PGNY) fell 3.9% in the afternoon session after a regulatory filing revealed a significant institutional investor had sharply reduced its stake in the company. The fertility and family-building benefits company saw its shares trade lower after a Form 13F filing, reported Friday, disclosed that investment firm Edgestream Partners L.P. had sold 105,195 shares. This sale represented a 56.4% reduction in the firm's position during the first quarter. A 13F is a quarterly report filed by institutional investment managers with over $100 million in assets under management to declare their U.S. equity holdings. While the sale occurred in a prior quarter, the release of the filing can influence current investor sentiment. The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks. Is now the time to buy Progyny? Access our full analysis report here, it's free. What Is The Market Telling Us Progyny's shares are somewhat volatile and have had 14 moves greater than 5% over the last year. In that context, today's move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business. Progyny is up 24.2% since the beginning of the year, but at $22.02 per share, it is still trading 24.4% below its 52-week high of $29.14 from July 2024. Investors who bought $1,000 worth of Progyny's shares 5 years ago would now be looking at an investment worth $843.68. Today's young investors likely haven't read the timeless lessons in Gorilla Game: Picking Winners In High Technology because it was written more than 20 years ago when Microsoft and Apple were first establishing their supremacy. But if we apply the same principles, then enterprise software stocks leveraging their own generative AI capabilities may well be the Gorillas of the future. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
10-07-2025
- Health
- Yahoo
Progyny Partners with ŌURA to Empower Women and Their Care Teams with Wearable Tech Data, Further Supporting Outcomes from Preconception to Menopause
NEW YORK, July 10, 2025 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a global leader in women's health and family building solutions, today announced a new partnership with ŌURA, maker of the world's leading smart ring, further empowering women to better understand and take action on their health through comprehensive data and personalized insights. By incorporating wearable data and insights from ŌURA into the care team decision-support process—from preconception to menopause—Progyny is engaging members upstream as they are being more proactive with their health. As a result, potential risks can be identified earlier, while also supporting a range of health goals, such as optimizing conception attempts or making sustainable lifestyle changes. 'The more women understand about their bodies, the more empowered they are to partner with their health providers and articulate their health status and goals. Whether you are focused on conceiving your first child or managing changing weight and sleep issues through menopause, understanding your personal data is powerful—physically and emotionally,' said Janet Choi, MD, Progyny Chief Medical Officer. 'Taking control with physiologic data from the Oura Ring further supports Progyny's focus on raising the bar and elevating health outcomes.' With the ability to continuously track key health metrics, such as sleep patterns, cycle insights, cardiovascular health, stress levels, and more, ŌURA helps women understand their bodies so they can achieve optimal health. For those trying to conceive, these insights can help pinpoint fertile windows and support reproductive planning. During perimenopause or menopause, they can help identify patterns, guide impactful lifestyle adjustments, and inform meaningful conversations with providers. When needed, care plans, including personalized recommendations around sleep, nutrition, movement, and stress to support the body's changing needs can be developed. 'Reproductive health management starts long before a doctor's visit—it begins with daily awareness of your body's patterns,' said Dorothy Kilroy, Chief Commercial Officer at ŌURA. 'By partnering with Progyny, we're bridging the gap between those daily health patterns and clinical care, helping people navigate fertility and family planning with greater clarity, confidence, and support. This collaboration brings Oura's powerful health signals into a setting where they can truly make a difference—guiding smarter care, earlier interventions, and more personalized journeys.' Oura Ring and Oura Membership will be available to Progyny clients, including employers and health plans, beginning in early 2026. About Progyny Progyny (Nasdaq: PGNY) is a global leader in women's health and family building solutions, trusted by the nation's leading employers, health plans and benefit purchasers. We envision a world where everyone can realize their dreams of family and ideal health. Our outcomes prove that comprehensive, inclusive, and intentionally designed solutions simultaneously benefit employers, patients, and physicians. Our benefits solution empowers patients with concierge support, coaching, education, and digital tools; provides access to a premier network of fertility and women's health specialists who use the latest science and technologies; drives optimal clinical outcomes; and reduces healthcare costs. Headquartered in New York City, Progyny has been recognized for its leadership and growth as a TIME100 Most Influential Company, CNBC Disruptor 50, Modern Healthcare's Best Places to Work in Healthcare, Forbes' Best Employers, Financial Times Fastest Growing Companies, Inc. 5000, Inc. Power Partners, and Crain's Fast 50 for NYC. For more information, visit For More Information, Please Contact: Media:Alexis Fordmedia@ Investors:James Hartinvestors@ while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
